Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Public ClinicalTrials.gov record NCT02735707. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19. REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19 in the United States of America.
Study identification
- NCT ID
- NCT02735707
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 20,000 participants
Conditions and interventions
Interventions
- Ceftriaxone Drug
- Moxifloxacin or Levofloxacin Drug
- Piperacillin-tazobactam Drug
- Ceftaroline Drug
- Amoxicillin-clavulanate Drug
- Standard course macrolide Drug
- Extended course macrolide Drug
- No systemic corticosteroid Other
- Fixed-duration Hydrocortisone Drug
- Shock-dependent hydrocortisone Drug
- Fixed-duration higher dose Hydrocortisone Drug
- No antiviral agent for influenza Other
- Five-days oseltamivir Drug
- Ten-days oseltamivir Drug
- No antiviral agent for COVID-19 Other
- Lopinavir / Ritonavir Drug
- Hydroxychloroquine Drug
- Hydroxychloroquine + lopinavir/ritonavir Drug
- Ivermectin Drug
- No immune modulation for COVID-19 Other
- Interferon beta-1a Drug
- Anakinra Drug
- Tocilizumab Drug
- Sarilumab Drug
- Local standard venous thromboprophylaxis Drug
- Therapeutic dose anticoagulation Drug
- Conventional low dose thromboprophylaxis Drug
- Intermediate dose thromboprophylaxis Drug
- Continuation of therapeutic dose anticoagulation Drug
- No immunoglobulin Other
- Convalescent plasma Biological
- Delayed administration of convalescent plasma Biological
- No vitamin C Other
- Vitamin C Drug
- No antiplatelet Other
- Aspirin Drug
- P2Y12 inhibitor Drug
- No simvastatin Other
- Simvastatin Drug
- Eritoran Drug
- Apremilast Drug
- Clinician-preferred mechanical ventilation strategy Procedure
- Protocolised mechanical ventilation strategy Procedure
- No renin-angiotensin system inhibitor Other
- Angiotensin converting enzyme inhibitor Drug
- Angiotensin Receptor Blockers Drug
- ARB + DMX-200 Drug
- No cysteamine Other
- Cysteamine Drug
- Fixed-duration dexamethasone Drug
- Baloxavir Marboxil Drug
- Five-days oseltamivir + baloxavir marboxil Drug
- Ten-days oseltamivir + baloxavir marboxil Drug
- No endothelial modulator Other
- Imatinib Drug
- No Immune Modulator for Influenza Other
- Baricitinib Drug
- Nirmatrelvir/ritonavir Drug
- Remdesivir Drug
- Nirmatrelvir/ritonavir + remdesivir Drug
Drug · Other · Biological + 1 more
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 10, 2016
- Primary completion
- Jan 31, 2026
- Completion
- Jan 31, 2028
- Last update posted
- Jul 11, 2024
2016 – 2028
United States locations
- U.S. sites
- 11
- U.S. states
- 11
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Florida | Jacksonville | Florida | 32209 | Recruiting |
| Augusta University | Augusta | Georgia | 30912 | Not yet recruiting |
| University of Illinois Health | Chicago | Illinois | 60612 | Recruiting |
| Tulane Medical Center | New Orleans | Louisiana | 70112 | Not yet recruiting |
| University of Michigan | Ann Arbor | Michigan | 48109 | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Recruiting |
| Wake Forest Baptist Health | Winston-Salem | North Carolina | 27157-1009 | Not yet recruiting |
| The Ohio State University Wexner Medical Center | Columbus | Ohio | 43210 | Recruiting |
| Oregon Health and Science University | Portland | Oregon | 97239-3098 | Recruiting |
| University of Pittsburgh Medical Centre | Pittsburgh | Pennsylvania | — | Recruiting |
| Brown University - Rhode Island Hospital | Providence | Rhode Island | 02903 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 397 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02735707, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 11, 2024 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02735707 live on ClinicalTrials.gov.